Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 9Recruiting 6Terminated 5Active not recruiting 5Unknown 2Suspended 1

Sponsor Class

OTHER 7INDUSTRY 2

Study Type

Interventional 9

Sponsor

Cancer Type

Lymphoid 643Other hematologic neoplasm 459Breast 338Plasma cell 184Myeloid 132Sarcoma 110CNS 87Dermatologic 85Classical hematology 54Gynecologic 50Gastrointestinal 46Genitourinary 43Thoracic 35Other solid neoplasm 24Head & Neck 13Tumor-Agnostic 9Other neoplasm 4Other 2Endocrine 2NET 1

Conditions

Neoplasms 7Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 32Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

9 trials
RecentStart dateEnrollment
Completed × Cyclophosphamide × Tumor-Agnostic × Clear all
NCT00420563 2026-03-16

PAL-ANGI

Centre Oscar Lambret

Phase 2 Completed
88 enrolled
Tumor-Agnostic

Neoplasms

NCT01374620 2026-03-16

PAL-ANGI2

Centre Oscar Lambret

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

NCT02775292 2025-07-30

NYM

Jonsson Comprehensive Cancer Center

Phase 1 Completed
1 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03296137 2024-10-26

Adoptive Cell Therapy Across Cancer Diagnoses

Herlev Hospital

Phase 1/2 Completed
25 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT01869192 2019-09-24

Phase II Trial for Large ER-Negative Breast Cancers

University of Colorado, Denver

Phase 2 Completed
72 enrolled 6 charts
Tumor-Agnostic

Neoplasms

NCT02004262 2018-06-04

ECLIPSE

Aduro Biotech, Inc.

Phase 2 Completed
303 enrolled 15 charts
Tumor-Agnostic

Neoplasms

NCT00246103 2017-02-23

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
82 enrolled
Tumor-Agnostic

Neoplasms

NCT00165451 2011-07-07

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

NCT00140075 2011-05-26

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Pfizer

Phase 3 Completed
606 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡